Pfizer Revises FY23 Revenue Guidance To $67B-$70B Vs. Consensus Of $61.01B And Prior Guidance Of $67B-$71B; Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6%-8%
Portfolio Pulse from Benzinga Newsdesk
Pfizer has revised its FY23 revenue guidance to $67B-$70B, compared to the consensus of $61.01B and prior guidance of $67B-$71B. The company also adjusted its 2023 non-COVID operational revenue growth expectation to 6%-8%.
August 01, 2023 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's revised FY23 revenue guidance is higher than the consensus, which could positively impact its stock. The company's non-COVID operational revenue growth expectation for 2023 has also been adjusted to 6%-8%.
Pfizer's revised revenue guidance for FY23 is higher than the market consensus, which could lead to a positive reaction from investors and a potential increase in the stock price. The adjustment in non-COVID operational revenue growth expectation for 2023 also indicates the company's confidence in its non-pandemic related operations, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100